Logo image of OLMA

OLEMA PHARMACEUTICALS INC (OLMA) Stock Fundamental Analysis

NASDAQ:OLMA - Nasdaq - US68062P1066 - Common Stock - Currency: USD

5.12  +0.02 (+0.39%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to OLMA. OLMA was compared to 553 industry peers in the Biotechnology industry. While OLMA has a great health rating, there are worries on its profitability. OLMA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OLMA has reported negative net income.
OLMA had a negative operating cash flow in the past year.
OLMA had negative earnings in each of the past 5 years.
OLMA had a negative operating cash flow in each of the past 5 years.
OLMA Yearly Net Income VS EBIT VS OCF VS FCFOLMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

OLMA has a Return On Assets of -31.47%. This is in the better half of the industry: OLMA outperforms 64.38% of its industry peers.
OLMA has a better Return On Equity (-33.61%) than 74.50% of its industry peers.
Industry RankSector Rank
ROA -31.47%
ROE -33.61%
ROIC N/A
ROA(3y)-37.4%
ROA(5y)-28.65%
ROE(3y)-40.93%
ROE(5y)-30.97%
ROIC(3y)N/A
ROIC(5y)N/A
OLMA Yearly ROA, ROE, ROICOLMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OLMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OLMA Yearly Profit, Operating, Gross MarginsOLMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, OLMA has more shares outstanding
Compared to 5 years ago, OLMA has more shares outstanding
There is no outstanding debt for OLMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OLMA Yearly Shares OutstandingOLMA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OLMA Yearly Total Debt VS Total AssetsOLMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 6.34 indicates that OLMA is not in any danger for bankruptcy at the moment.
OLMA's Altman-Z score of 6.34 is fine compared to the rest of the industry. OLMA outperforms 79.57% of its industry peers.
There is no outstanding debt for OLMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.34
ROIC/WACCN/A
WACCN/A
OLMA Yearly LT Debt VS Equity VS FCFOLMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 15.22 indicates that OLMA has no problem at all paying its short term obligations.
OLMA has a better Current ratio (15.22) than 88.61% of its industry peers.
OLMA has a Quick Ratio of 15.22. This indicates that OLMA is financially healthy and has no problem in meeting its short term obligations.
OLMA's Quick ratio of 15.22 is amongst the best of the industry. OLMA outperforms 88.61% of its industry peers.
Industry RankSector Rank
Current Ratio 15.22
Quick Ratio 15.22
OLMA Yearly Current Assets VS Current LiabilitesOLMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.50% over the past year.
EPS 1Y (TTM)0.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, OLMA will show a decrease in Earnings Per Share. The EPS will decrease by -2.15% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.32%
EPS Next 2Y5.35%
EPS Next 3Y5.98%
EPS Next 5Y-2.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OLMA Yearly Revenue VS EstimatesOLMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
OLMA Yearly EPS VS EstimatesOLMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OLMA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OLMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OLMA Price Earnings VS Forward Price EarningsOLMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OLMA Per share dataOLMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.35%
EPS Next 3Y5.98%

More info and screens

0

5. Dividend

5.1 Amount

OLMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OLEMA PHARMACEUTICALS INC

NASDAQ:OLMA (7/31/2025, 3:22:31 PM)

5.12

+0.02 (+0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12
Inst Owners98.67%
Inst Owner Change0.01%
Ins Owners4.18%
Ins Owner Change0%
Market Cap350.31M
Analysts85.71
Price Target24.65 (381.45%)
Short Float %11.65%
Short Ratio10.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.34%
Min EPS beat(2)21.88%
Max EPS beat(2)30.8%
EPS beat(4)3
Avg EPS beat(4)13.83%
Min EPS beat(4)-1.8%
Max EPS beat(4)30.8%
EPS beat(8)6
Avg EPS beat(8)12.09%
EPS beat(12)8
Avg EPS beat(12)8.13%
EPS beat(16)10
Avg EPS beat(16)5.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.46%
EPS NQ rev (1m)15.7%
EPS NQ rev (3m)42.15%
EPS NY rev (1m)0%
EPS NY rev (3m)26.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-1.97
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.82
OCFYN/A
SpS0
BVpS5.6
TBVpS5.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.47%
ROE -33.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.4%
ROA(5y)-28.65%
ROE(3y)-40.93%
ROE(5y)-30.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.22
Quick Ratio 15.22
Altman-Z 6.34
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)46.82%
Cap/Depr(5y)345.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
EPS Next Y21.32%
EPS Next 2Y5.35%
EPS Next 3Y5.98%
EPS Next 5Y-2.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.26%
EBIT Next 3Y-13.34%
EBIT Next 5YN/A
FCF growth 1Y-47.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-47.63%
OCF growth 3YN/A
OCF growth 5YN/A